Novartis seeks broader ‘incremental’ IP in India with Glivec case
This article was originally published in Scrip
As Novartis awaits the Supreme Court's verdict in the much publicized Glivec (imatinib mesylate) case in India, the Swiss multinational has stressed that it is seeking a predictable interpretation of the controversial Section 3(d) provision of India's patent law, which it believes should broadened to give due weight to improved safety, among other factors, and not just improved efficacy.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.